United States CAR-T Cell Therapy Market By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (He

United States CAR-T Cell Therapy Market By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, Competition Forecast & Opportunities, 2028.

United States CAR-T Cell Therapy Market is expected to grow at an impressive rate during the forecast period 2024-2028. The major factors include the rising prevalence of cancer consisting of myeloma, lymphoma, leukemia, etc., rapidly expanding clinical trial activities, a rise in awareness of CAR-T cell therapy, and recent commercialization of CAR-T cell therapy.

CAR-T (Chimeric Antigen Receptor T-cell) therapy is an innovative type of immunotherapy that involves genetically modifying a patient's own T- cells to recognize and attack cancer cells. This therapy has shown remarkable results in the treatment of certain types of blood cancer, such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). According to Leukemia and Lymphoma Society, in 2021, an estimated 34,920 new cases of myeloma (19,320 males and 15,600 females) were expected to be diagnosed in the United States (U.S.), and an estimated 138,415 people are living with myeloma in U.S. Additionally, in 2021, 61,090 people were expected to be diagnosed with leukemia in the U.S., and an estimated 397,501 people are living with leukemia in the U.S.

The Chimeric Antigen Receptor (CAR) T-cell therapy is for the treatment of hematologic malignancies, i.e., the cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system like leukemia, lymphoma, and multiple myeloma, etc. Another factor driving the market growth is the increasing demand for personalized and targeted cancer therapies. CAR-T cell therapy is a highly personalized treatment that involves modifying the patient's immune cells to target cancer cells, making it a more effective and precise treatment option for certain types of cancers.

According to Global Cancer Observatory, in 2020, around 1 0,55,117 new cancer cases were reported in the United States of America. Moreover, the other factor includes the increasing investments in the healthcare sector, the major involvement of market players, and the increase in the number of funding activities. Various initiatives and awareness programs are taken by government or private organizations to raise awareness about diseases and treatments and information about the availability of more advanced technologies and procedures at healthcare facilities.

Rising Prevalence of Cancer

In the United States, cancer is the leading cause of death. This is due to the physical carcinogens, such as ultraviolet and ionizing radiation; chemical carcinogens, such as asbestos, components of tobacco smoke, alcohol, aflatoxin (a food contaminant), and arsenic (a drinking water contaminant) and biological carcinogens, such as infections from certain viruses, bacteria, or parasites, and unhealthy lifestyle. According to the American Cancer Society, more than 1.8 million people were diagnosed with cancer in 2020. For instance, an estimated 1,519,907 people in the United States are suffering from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPNs). Therefore, CAR-T Cell therapy enables the T cells to target cell surface antigens for getting management and treatment of cancer. Thereby, it is expected to drive the growth of the CAR-T Cell Therapy Market in the United States.

Recent Developments

In 2017, the first two autologous CAR T-cell therapies were approved by the U.S. Food and Drug Administration, namely tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with large B-cell lymphoma (refractory or in second or later relapse), and axicabtagene ciloleucel (Yescarta), for the treatment of adults with large B-cell lymphoma (LBCL) who either did not respond to first-line standard chemotherapy or relapsed within 12 months of chemotherapy.

In 2020, the FDA gave approval for brexucabtagene autoleucel (TecartusTM) for the treatment of adults with r/r MCL and adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Additionally, in 2021, the FDA gave the approval for Lisocabtagene maraleucel (Breyanzi) or the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy and idecabtagene vicleucel (Abecma) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy.

Recently, in March 2022, Ciltacabtagene autoleucel (CarvyktiTM) was approved by FDA for the treatment of adult patients with relapsed or refractory multiple myeloma who have already tried four or more prior lines of therapy.

Commercialization of CAR-T Cell Therapy

The commercialization of CAR-T Cell Therapy is the key challenge resulting in restricting the growth of the market in the forecast period. This is due to the complex manufacturing and supply chain, high-touch commercial model, and reimbursement cost. All CAR T-cell therapies are autologous, resulting in complex, costly manufacturing and supply chains. For instance, in the United States, a limited number of certified academic medical centers (AMCs) offer commercial CAR T, often requiring patients to travel long distances to receive care. This is due to the limited number of commercial sites, which involves extensive preparation and certification to offer CAR T therapies.

Increasing Investments in Research and Development & Favorable Regulatory Environment

Research and development are crucial for the advancement of CAR-T cell therapy. The United States has a significant advantage in this regard, as it is home to some of the world's leading research institutions and pharmaceutical companies. These companies are investing heavily in CAR-T cell therapy research, which is driving the market's growth. Additionally, the FDA discovered an improved environment to give approval of two CAR-T cell therapies for use in the United States, which has provided a boost to the market. The regulatory environment for CAR-T cell therapy is favorable, which has encouraged more companies to invest in this area. The FDA's expedited review process for breakthrough therapies has helped speed up the approval process for CAR-T cell therapies, which has contributed to market growth.

Market Segmentation

The United States CAR-T Cell Therapy Market can be segmented into product type, tumor type, indication, treatment type, targeted antigen, end user, and region. By product type, the market can be segmented into Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), and others. Based on tumor type, the market can be segmented into Hematological Malignancies, and Solid Tumors. Based on indication, the market can be segmented into Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (F.L.), Mantle Cell Lymphoma (MCL), and Others. Based on treatment type, the market can be segmented into Single Treatment and Combination Treatment. Based on targeted antigen, the market can be segmented into CD 19, BCMA (B-Cell Maturation Antigen), and Others. Based on end-user, the market can be segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others.

Market Players

Gilead Sciences, Inc (U.S.), Novartis United States, AbbVie Inc., Myriad Genetics, NeoGenomics Laboratories, Intellia Therapeutics (U.S.), Agilent Technologies, Inc. (U.S.), Abcam plc., Bio-Techne. (ExoDx), Sangamo Therapeutics, Inc. (U.S.), etc., are some of the leading companies operating in the market.

Report Scope:

In this report, United States CAR-T Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States CAR-T Cell Therapy Market, By Product Type
• Yescarta (Axicabtagene Ciloleucel)
• Kymriah (Tisagenlecleucel)
• Tecartus (Brexucabtagene Autoleucel)
• Breyanzi (Lisocabtagene Maraleucel)
• Abecma (Idecabtagene Vicleucel)
• Others
• United States CAR-T Cell Therapy Market, Tumor Type
• Hematological Malignancies
• Solid Tumors
• United States CAR-T Cell Therapy Market, By Indication
• Diffused Large B-Cell Lymphoma (DLBCL)
• Acute Lymphoblastic Leukemia (ALL)
• Follicular Lymphoma (FL)
• Mantle Cell Lymphoma (MCL)
• Others
• United States CAR-T Cell Therapy Market, By Treatment Type
• Single Treatment
• Combination Treatment
• United States CAR-T Cell Therapy Market, By Targeted Antigen
• CD 19
• BCMA (B-Cell Maturation Antigen)
• Others
• United States CAR-T Cell Therapy Market, By End User
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others
• United States CAR-T Cell Therapy Market, By Region:
• Northeast
• Midwest
• South
• West

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in United States CAR-T Cell Therapy Market

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order. Single User license will be delivered in PDF format without printing rights